ID   PPARG_HUMAN    STANDARD;      PRT;   505 AA.
AC   P37231; O00684; O00710; O14515; Q15178; Q15179; Q15180; Q15832;
AC   Q86U60; Q96J12;
DT   01-OCT-1994, integrated into UniProtKB/Swiss-Prot.
DT   27-APR-2001, sequence version 3.
DT   18-APR-2006, entry version 85.
DE   Peroxisome proliferator-activated receptor gamma (PPAR-gamma).
GN   Name=PPARG; Synonyms=NR1C3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Heart;
RX   MEDLINE=97218249; PubMed=9065481; DOI=10.1074/jbc.272.12.8071;
RA   Mukherjee R., Jow L., Croston G.E., Paterniti J.R. Jr.;
RT   "Identification, characterization, and tissue distribution of human
RT   peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2
RT   versus PPARgamma1 and activation with retinoid X receptor agonists and
RT   antagonists.";
RL   J. Biol. Chem. 272:8071-8076(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Fat body;
RX   MEDLINE=96295505; PubMed=8702406; DOI=10.1006/bbrc.1996.1044;
RA   Elbrecht A., Chen Y., Cullinan C.A., Hayes N., Leibowitz M.D.,
RA   Moller D.E., Berger J.;
RT   "Molecular cloning, expression and characterization of human
RT   peroxisome proliferator activated receptors gamma 1 and gamma 2.";
RL   Biochem. Biophys. Res. Commun. 224:431-437(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Adipose tissue;
RX   MEDLINE=97289627; PubMed=9144532; DOI=10.1006/bbrc.1997.6446;
RA   Yanase T., Yashiro T., Takitani K., Kato S., Taniguchi S.,
RA   Takayanagi R., Nawata H.;
RT   "Differential expression of PPAR gamma1 and gamma2 isoforms in human
RT   adipose tissue.";
RL   Biochem. Biophys. Res. Commun. 233:320-324(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Bone marrow;
RX   MEDLINE=95307078; PubMed=7787419;
RA   Greene M.E., Blumberg B., McBride O.W., Yi H.F., Kronquist K.,
RA   Kwan K., Hsieh L., Greene G., Nimer S.D.;
RT   "Isolation of the human peroxisome proliferator activated receptor
RT   gamma cDNA: expression in hematopoietic cells and chromosomal
RT   mapping.";
RL   Gene Expr. 4:281-299(1995).
RN   [5]
RP   SEQUENCE REVISION TO 36; 37; 213; 214 AND 240.
RA   Greene M.E.;
RL   Submitted (DEC-2001) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   MEDLINE=98016122; PubMed=9356045;
RA   Okazawa H., Mori H., Tamori Y., Araki S., Niki T., Masugi J.,
RA   Kawanishi M., Kubota T., Shinoda H., Kasuga M.;
RT   "No coding mutations are detected in the peroxisome proliferator-
RT   activated receptor-gamma gene in Japanese patients with lipoatrophic
RT   diabetes.";
RL   Diabetes 46:1904-1906(1997).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   MEDLINE=96305359; PubMed=8706692;
RA   Lambe K.G., Tugwood J.D.;
RT   "A human peroxisome-proliferator-activated receptor-gamma is activated
RT   by inducers of adipogenesis, including thiazolidinedione drugs.";
RL   Eur. J. Biochem. 239:1-7(1996).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ALA-12.
RA   Rieder M.J., da Ponte S.H., Kuldanek S.A., Rajkumar N., Smith J.D.,
RA   Toth E.J., Nickerson D.A.;
RT   "SeattleSNPs. NHLBI HL66682 program for genomic applications, UW-
RT   FHCRC, Seattle, WA (URL: http://pga.gs.washington.edu).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA   Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA   Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA   Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA   Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA   Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA   Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA   Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA   Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA   Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA   Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA   Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA   Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA   Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA   Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA   Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA   Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA   Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT   "Generation and initial analysis of more than 15,000 full-length human
RT   and mouse cDNA sequences.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN   [11]
RP   INTERACTION WITH NCOA6.
RX   MEDLINE=20148724; PubMed=10681503; DOI=10.1074/jbc.275.8.5308;
RA   Caira F., Antonson P., Pelto-Huikko M., Treuter E., Gustafsson J.-A.;
RT   "Cloning and characterization of RAP250, a nuclear receptor
RT   coactivator.";
RL   J. Biol. Chem. 275:5308-5317(2000).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS).
RX   MEDLINE=20337987; PubMed=10882139; DOI=10.1016/S1097-2765(00)80448-7;
RA   Gampe R.T. Jr., Montana V.G., Lambert M.H., Miller A.B., Bledsoe R.K.,
RA   Milburn M.V., Kliewer S.A., Willson T.M., Xu H.E.;
RT   "Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the
RT   molecular basis of heterodimerization among nuclear receptors.";
RL   Mol. Cell 5:545-555(2000).
RN   [13]
RP   VARIANT ALA-12.
RX   MEDLINE=98086341; PubMed=9425261; DOI=10.1006/bbrc.1997.7798;
RA   Yen C.-J., Beamer B.A., Negri C., Silver K., Brown K.A., Yarnall D.P.,
RA   Burns D.K., Roth J., Shuldiner A.R.;
RT   "Molecular scanning of the human peroxisome proliferator activated
RT   receptor gamma (hPPAR-gamma) gene in diabetic Caucasians:
RT   identification of a pro12ala PPAR-gamma-2 missense mutation.";
RL   Biochem. Biophys. Res. Commun. 241:270-274(1997).
RN   [14]
RP   VARIANT OBESITY GLN-113.
RX   MEDLINE=98418646; PubMed=9753710; DOI=10.1056/NEJM199810013391403;
RA   Ristow M., Muller-Wieland D., Pfeiffer A., Krone W., Kahn C.R.;
RT   "Obesity associated with a mutation in a genetic regulator of
RT   adipocyte differentiation.";
RL   N. Engl. J. Med. 339:953-959(1998).
RN   [15]
RP   VARIANT ALA-12.
RX   MEDLINE=99337654; PubMed=10407229; DOI=10.1530/eje.0.1410090;
RA   Hamann A., Munzberg H., Buttron P., Busing B., Hinney A., Mayer H.,
RA   Siegfried W., Hebebrand J., Greten H.;
RT   "Missense variants in the human peroxisome proliferator-activated
RT   receptor-gamma2 gene in lean and obese subjects.";
RL   Eur. J. Endocrinol. 141:90-92(1999).
RN   [16]
RP   VARIANTS COLON CANCER PRO-314 AND HIS-316, AND VARIANT ALA-12.
RX   MEDLINE=99322672; PubMed=10394368; DOI=10.1016/S1097-2765(01)80012-5;
RA   Sarraf P., Mueller E., Smith W.M., Wright H.M., Kum J.B.,
RA   Aaltonen L.A., de la Chapelle A., Spiegelman B.M., Eng C.;
RT   "Loss-of-function mutations in PPAR-gamma associated with human colon
RT   cancer.";
RL   Mol. Cell 3:799-804(1999).
RN   [17]
RP   VARIANTS DIABETES MET-318 AND LEU-495.
RX   MEDLINE=20085964; PubMed=10622252; DOI=10.1038/47254;
RA   Barroso I., Gurnell M., Crowley V.E.F., Agostini M., Schwabel J.W.,
RA   Soos M.A., Masien G.L., Williams T.D.M., Lewis H., Schafer A.J.,
RA   Chatterjee V.K.K., O'Rahilly S.;
RT   "Dominant negative mutations in human PPAR-gamma associated with
RT   severe insulin resistance, diabetes mellitus and hypertension.";
RL   Nature 402:880-883(1999).
RN   [18]
RP   VARIANT FPLD3 LEU-388.
RX   PubMed=12453919;
RA   Hegele R.A., Cao H., Frankowski C., Mathews S.T., Leff T.;
RT   "PPARG F388L, a transactivation-deficient mutant, in familial partial
RT   lipodystrophy.";
RL   Diabetes 51:3586-3590(2002).
RN   [19]
RP   VARIANT FPLD3 CYS-425.
RX   MEDLINE=21648844; PubMed=11788685; DOI=10.1210/jc.87.1.408;
RA   Agarwal A.K., Garg A.;
RT   "A novel heterozygous mutation in peroxisome proliferator-activated
RT   receptor-gamma gene in a patient with familial partial
RT   lipodystrophy.";
RL   J. Clin. Endocrinol. Metab. 87:408-411(2002).
RN   [20]
RP   ASSOCIATION OF VARIANT ALA-12 WITH CIMT.
RX   PubMed=15356014; DOI=10.1210/jc.2003-032120;
RA   Temelkova-Kurktschiev T., Hanefeld M., Chinetti G., Zawadzki C.,
RA   Haulon S., Kubaszek A., Koehler C., Leonhardt W., Staels B.,
RA   Laakso M.;
RT   "Ala12Ala genotype of the peroxisome proliferator-activated receptor
RT   gamma2 protects against atherosclerosis.";
RL   J. Clin. Endocrinol. Metab. 89:4238-4242(2004).
CC   -!- FUNCTION: Receptor that binds peroxisome proliferators such as
CC       hypolipidemic drugs and fatty acids. Once activated by a ligand,
CC       the receptor binds to a promoter element in the gene for acyl-CoA
CC       oxidase and activates its transcription. It therefore controls the
CC       peroxisomal beta-oxidation pathway of fatty acids. Key regulator
CC       of adipocyte differentiation and glucose homeostasis.
CC   -!- SUBUNIT: Forms a heterodimer with the retinoic acid receptor RXR-
CC       alpha called adipocyte-specific transcription factor ARF6.
CC       Interacts with NCOA6 coactivator, leading to a strong increase in
CC       transcription of target genes. Interacts with coactivator PPARBP,
CC       leading to a mild increase in transcription of target genes (By
CC       similarity).
CC   -!- INTERACTION:
CC       O60869:EDF1; NbExp=4; IntAct=EBI-781384, EBI-781301;
CC       Q09472:EP300; NbExp=1; IntAct=EBI-781384, EBI-447295;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC         Comment=Additional isoforms seem to exist;
CC       Name=2;
CC         IsoId=P37231-1; Sequence=Displayed;
CC       Name=1;
CC         IsoId=P37231-2; Sequence=VSP_003645;
CC   -!- TISSUE SPECIFICITY: Highest expression in adipose tissue. Lower in
CC       skeletal muscle, spleen, heart and liver. Also are detectable in
CC       placenta, lung and ovary.
CC   -!- DISEASE: Defects in PPARG can lead to type 2 insulin-resistant
CC       diabetes and hyptertension.
CC   -!- DISEASE: Defects in PPARG could play a role in the genetic
CC       predisposition to obesity.
CC   -!- DISEASE: Defects in PPARG may be associated with colon cancer.
CC   -!- DISEASE: Defects in PPARG are the cause of familial partial
CC       lipodystrophy type 3 (FPLD3) [MIM:604367]. Familial partial
CC       lipodystrophies (FPLD) are a heterogeneous group of genetic
CC       disorders characterized by marked loss of subcutaneous (sc) fat
CC       from the extremities. Affected individuals show an increased
CC       preponderance of insulin resistance, diabetes mellitus and
CC       dyslipidemia.
CC   -!- DISEASE: Variation in PPARG is associated with carotid intimal
CC       medial thickness 1 (CIMT1) [MIM:609338]. CIMT is a measure of
CC       atherosclerosis that is independently associated with traditional
CC       atherosclerotic cardiovascular disease risk factors and coronary
CC       atherosclerotic burden. 35 to 45% of the variability in
CC       multivariable-adjusted CIMT is explained by genetic factors.
CC   -!- SIMILARITY: Belongs to the nuclear hormone receptor family. NR1
CC       subfamily.
CC   -!- SIMILARITY: Contains 1 nuclear receptor DNA-binding domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U79012; AAC51248.1; -; mRNA.
DR   EMBL; U63415; AAB04028.1; -; mRNA.
DR   EMBL; D83233; BAA18949.1; -; mRNA.
DR   EMBL; L40904; AAA80314.2; ALT_INIT; mRNA.
DR   EMBL; AB005526; BAA23354.1; ALT_INIT; Genomic_DNA.
DR   EMBL; X90563; CAA62152.1; ALT_INIT; mRNA.
DR   EMBL; X90563; CAA62153.1; -; mRNA.
DR   EMBL; AY157024; AAN38992.2; -; Genomic_DNA.
DR   EMBL; BT007281; AAP35945.1; ALT_INIT; mRNA.
DR   EMBL; BC006811; AAH06811.1; ALT_INIT; mRNA.
DR   UniGene; Hs.162646; -.
DR   PDB; 1FM6; X-ray; D/X=234-505.
DR   PDB; 1FM9; X-ray; D=234-505.
DR   PDB; 1I7I; X-ray; A/B=225-505.
DR   PDB; 1K74; X-ray; D=234-505.
DR   PDB; 1NYX; X-ray; A/B=230-505.
DR   PDB; 1PRG; X-ray; A/B=235-504.
DR   PDB; 1RDT; X-ray; D=235-505.
DR   PDB; 1WM0; X-ray; X=-.
DR   PDB; 1ZGY; X-ray; A=234-505.
DR   PDB; 2PRG; X-ray; A/B=235-505.
DR   PDB; 3PRG; X-ray; A=232-505.
DR   PDB; 4PRG; X-ray; A/B/C/D=235-504.
DR   IntAct; P37231; -.
DR   TRANSFAC; T03731; -.
DR   Ensembl; ENSG00000132170; Homo sapiens.
DR   H-InvDB; HIX0003064; -.
DR   HGNC; HGNC:9236; PPARG.
DR   MIM; 601487; gene.
DR   MIM; 604367; phenotype.
DR   MIM; 609338; phenotype.
DR   GO; GO:0004879; F:ligand-dependent nuclear receptor activity; TAS.
DR   GO; GO:0005515; F:protein binding; IPI.
DR   GO; GO:0003700; F:transcription factor activity; TAS.
DR   GO; GO:0006091; P:generation of precursor metabolites and energy; TAS.
DR   GO; GO:0006629; P:lipid metabolism; TAS.
DR   GO; GO:0006357; P:regulation of transcription from RNA polyme...; TAS.
DR   GO; GO:0007584; P:response to nutrient; TAS.
DR   GO; GO:0007165; P:signal transduction; TAS.
DR   GO; GO:0050872; P:white fat cell differentiation; TAS.
DR   InterPro; IPR003074; 1Cnucl_rcpt.
DR   InterPro; IPR003077; 1Cnucl_rcpt_G.
DR   InterPro; IPR001628; Hrmn_rcpt_DNA_bd.
DR   InterPro; IPR000536; Hrmn_rcpt_lig_bd.
DR   InterPro; IPR001723; Str_hrmn_rcpt.
DR   InterPro; IPR008946; Str_rcpt_lig_bd.
DR   PANTHER; PTHR11865:SF32; 1Cnucl_receptor; 1.
DR   Pfam; PF00104; Hormone_recep; 1.
DR   Pfam; PF00105; zf-C4; 1.
DR   PRINTS; PR01288; PROXISOMEPAR.
DR   PRINTS; PR01291; PROXISOMPAGR.
DR   PRINTS; PR00398; STRDHORMONER.
DR   PRINTS; PR00047; STROIDFINGER.
DR   ProDom; PD000035; Znf_C4steroid; 1.
DR   SMART; SM00430; HOLI; 1.
DR   SMART; SM00399; ZnF_C4; 1.
DR   PROSITE; PS00031; NUCLEAR_REC_DBD_1; 1.
DR   PROSITE; PS51030; NUCLEAR_REC_DBD_2; 1.
KW   3D-structure; Activator; Alternative splicing; Diabetes mellitus;
KW   Disease mutation; DNA-binding; Metal-binding; Nuclear protein;
KW   Obesity; Phosphorylation; Polymorphism; Receptor; Transcription;
KW   Transcription regulation; Zinc; Zinc-finger.
FT   CHAIN         1    505       Peroxisome proliferator-activated
FT                                receptor gamma.
FT                                /FTId=PRO_0000053492.
FT   DNA_BIND    136    210       Nuclear receptor.
FT   ZN_FING     139    159       NR C4-type.
FT   ZN_FING     176    198       NR C4-type.
FT   REGION      318    505       Ligand-binding (Potential).
FT   MOD_RES     112    112       Phosphoserine (by MAPK) (By similarity).
FT   VARSPLIC      1     30       Missing (in isoform 1).
FT                                /FTId=VSP_003645.
FT   VARIANT      12     12       P -> A (significant independent
FT                                determinant of CIMT; may protect from
FT                                early atherosclerosis in subjetc at risk
FT                                for diabetes; dbSNP:1801282).
FT                                /FTId=VAR_010723.
FT   VARIANT      40     40       P -> A (in dbSNP:1805192).
FT                                /FTId=VAR_016116.
FT   VARIANT     113    113       P -> Q (in obesity; dbSNP:1800571).
FT                                /FTId=VAR_010724.
FT   VARIANT     314    314       Q -> P (in colon cancer; sporadic;
FT                                somatic mutation; loss of ligand-
FT                                binding).
FT                                /FTId=VAR_010725.
FT   VARIANT     316    316       R -> H (in colon cancer; sporadic;
FT                                somatic mutation; partial loss of ligand-
FT                                binding).
FT                                /FTId=VAR_010726.
FT   VARIANT     318    318       V -> M (in diabetes).
FT                                /FTId=VAR_010727.
FT   VARIANT     388    388       F -> L (in FPLD3).
FT                                /FTId=VAR_022700.
FT   VARIANT     425    425       R -> C (in FPLD3).
FT                                /FTId=VAR_022701.
FT   VARIANT     495    495       P -> L (in diabetes).
FT                                /FTId=VAR_010728.
FT   CONFLICT     36     37       MP -> IA (in Ref. 3).
FT   CONFLICT    213    214       MP -> IA (in Ref. 3).
FT   CONFLICT    240    240       R -> RQ (in Ref. 3).
FT   CONFLICT    424    426       Missing (in Ref. 6).
FT   HELIX       235    253
FT   STRAND      255    256
FT   HELIX       258    265
FT   STRAND      266    267
FT   STRAND      270    271
FT   STRAND      275    277
FT   STRAND      279    279
FT   HELIX       280    285
FT   TURN        286    286
FT   STRAND      287    288
FT   STRAND      290    292
FT   STRAND      294    296
FT   STRAND      298    298
FT   TURN        301    302
FT   STRAND      303    303
FT   HELIX       305    328
FT   TURN        329    330
FT   STRAND      331    331
FT   TURN        332    333
FT   HELIX       334    336
FT   STRAND      337    337
FT   HELIX       339    360
FT   TURN        361    361
FT   STRAND      362    363
FT   TURN        364    365
FT   STRAND      366    369
FT   TURN        370    373
FT   STRAND      374    377
FT   HELIX       378    383
FT   STRAND      384    384
FT   TURN        386    390
FT   STRAND      391    392
FT   HELIX       393    403
FT   TURN        404    405
FT   HELIX       409    420
FT   TURN        421    421
FT   TURN        423    424
FT   STRAND      425    425
FT   TURN        426    427
FT   STRAND      429    429
FT   HELIX       431    452
FT   TURN        454    455
FT   TURN        457    458
FT   HELIX       459    484
FT   TURN        485    487
FT   TURN        489    490
FT   HELIX       495    501
FT   TURN        502    503
SQ   SEQUENCE   505 AA;  57620 MW;  3933EFF36A0E4CAF CRC64;
     MGETLGDSPI DPESDSFTDT LSANISQEMT MVDTEMPFWP TNFGISSVDL SVMEDHSHSF
     DIKPFTTVDF SSISTPHYED IPFTRTDPVV ADYKYDLKLQ EYQSAIKVEP ASPPYYSEKT
     QLYNKPHEEP SNSLMAIECR VCGDKASGFH YGVHACEGCK GFFRRTIRLK LIYDRCDLNC
     RIHKKSRNKC QYCRFQKCLA VGMSHNAIRF GRMPQAEKEK LLAEISSDID QLNPESADLR
     ALAKHLYDSY IKSFPLTKAK ARAILTGKTT DKSPFVIYDM NSLMMGEDKI KFKHITPLQE
     QSKEVAIRIF QGCQFRSVEA VQEITEYAKS IPGFVNLDLN DQVTLLKYGV HEIIYTMLAS
     LMNKDGVLIS EGQGFMTREF LKSLRKPFGD FMEPKFEFAV KFNALELDDS DLAIFIAVII
     LSGDRPGLLN VKPIEDIQDN LLQALELQLK LNHPESSQLF AKLLQKMTDL RQIVTEHVQL
     LQVIKKTETD MSLHPLLQEI YKDLY
//
